Compare Archer-Daniels-Midland Co (ADM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Mesoblast Limited — how do they compare? Archer-Daniels-Midland Co trades at $80.5 (market cap $38.78B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Archer-Daniels-Midland Co is far larger — about 17.5× Mesoblast Limited's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ADM | MESO | |
|---|---|---|
Market Cap | $38.78B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $87.32 | $20.96 |
52-Week Low | $56.00 | $12.88 |
Enterprise Value | $47.03B | $2.21B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $80.49, up 5.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has declined from $101.6B in 2022 to $80.3B in 2025, but net income margin improved to 2.16% in 2025. The company raised its 2026 outlook after Q2 results, citing biofuels and nutrition strength. Valuation ratios include a P/E of 21.98 and P/S of 0.48, indicating potential undervaluation relative to earnings growth prospects.
Outlook is positive with analyst consensus price target of $88.00, though execution risks and competitive pressures remain. Investment opportunity lies in continued margin expansion and biofuel demand, while risks include volatile commodity prices and debt levels. The stock offers a dividend yield supported by 379 consecutive quarterly payments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
